Baqsimi Powder
Product Images NDC 85766-212

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Baqsimi (NDC 85766-212). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sportpharm Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
Line chart showing mean glucose levels (mg/dL) over time (minutes) after administration of 3 mg Baqsimi nasal powder. The glucose level starts around 54 mg/dL at time 0, rises steadily to approximately 185 mg/dL by 60 minutes, and then plateaus through 90 minutes.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A line graph depicting mean glucose levels (mg/dL) over time (minutes) for four age groups: 1 to <4 years, 4 to <8 years, 8 to <12 years, and 12 to <17 years. Each group is represented by a distinct marker, showing glucose changes from 0 to 90 minutes with varying patterns among the age ranges.*
FDA Label Image

Ifu1 (Ifu1)

Ifu1 (Ifu1)
An instructional diagram showing components of a Baqsimi 3 mg nasal powder device. Labeled parts include the Tube, Lid, Tip, Device, Plunger, and a Green Line indicator, illustrating assembly or usage steps for this glucagon nasal powder product by Sportpharm LLC.*
FDA Label Image

Ifu2 (Ifu2)

Ifu2 (Ifu2)
An instructional diagram shows a yellow nasal spray container with a red nasal applicator tip under shrink wrap, labeled to identify the shrink wrap covering the applicator.*
FDA Label Image

Ifu3 (Ifu3)

Ifu3 (Ifu3)
An instructional illustration showing the assembly of the Baqsimi nasal powder device. It depicts a hand holding the yellow tube and another hand holding the white device with a green indicator, with labels identifying the tube, lid, and device components.*
FDA Label Image

Ifu4 (Ifu4)

Ifu4 (Ifu4)
An instructional diagram showing a hand holding a Baqsimi nasal powder device. Labeled parts include the tip, plunger, and a green line near the plunger, emphasizing the device's correct handling before administration.*
FDA Label Image

Ifu5 (Ifu5)

Ifu5 (Ifu5)
An instructional illustration showing a hand holding a Baqsimi nasal powder delivery device near a nose, demonstrating how to administer the 3 mg glucagon nasal powder dose by inserting the device into the nostril. A green number "2" in a circle indicates this is the second step of the instructions.*
FDA Label Image

Ifu6 (Ifu6)

Ifu6 (Ifu6)
An instructional illustration showing a hand holding a nasal spray device positioned near the nostril. Dotted lines indicate the spray being released into the nose, with a number 3 in a green circle indicating step three in the usage process.*
FDA Label Image

Ifu7 (Ifu7)

Ifu7 (Ifu7)
Baqsimi 3 mg nasal powder packaging label shows a predominantly yellow and white box with an area designated for the expiration date, which is highlighted. The label includes orange and white elements at one end. The product is labeled by Sportpharm LLC.*
FDA Label Image

Label (Label)

Label (Label)
Baqsimi (glucagon) nasal powder 3 mg packaging label. The label indicates it contains 3 units, NDC 85766-212-03, labeled by Sportpharm and marketed by Amphastar Pharmaceuticals, Inc. It includes a QR code and regulatory information, with cautions and storage instructions.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram showing the amino acid sequence of the peptide glucagon, the active ingredient in Baqsimi nasal powder 3 mg, labeled with each residue's single-letter and three-letter codes in a chain from the N-terminus to the C-terminus.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.